open access

Vol 3, No 4 (2006)
Review paper
Published online: 2006-12-08
Get Citation

Metabolic syndrome prevalence, morbidity and mortality in patients with schizophrenia. Therapeutic restrictions and choice of adequate antipsychotic

Jolanta Rabe-Jabłońska
Psychiatria 2006;3(4):148-153.

open access

Vol 3, No 4 (2006)
Prace poglądowe - nadesłane
Published online: 2006-12-08

Abstract

The aim of this article was the presentation of recent data regarding morbidity, mortality, their causes, and prevalence of metabolic syndrome in schizophrenic patients. Metabolic syndrome is connected with high risk of cardiovascular diseases development. Early diagnose of this syndrome is especially important in population of people with mental disorders, because some disorders, such as schizophrenia, are associated with presence of some symptoms of metabolic syndrome, probably previous to pharmacotherapy. Some drugs used in treatment of mental disorders (among others antypsychotics: both typical and atypical) have unfavourable influence on weight gain, lipids profile and glucose metabolism disorders. In this article I present information about influence of antypsychotic treatment on the risk of metabolic syndrome development, can help to choose adquate, save pharmacotherapy for each patient, especially for patients with single symptoms of metabolic syndrome.

Abstract

The aim of this article was the presentation of recent data regarding morbidity, mortality, their causes, and prevalence of metabolic syndrome in schizophrenic patients. Metabolic syndrome is connected with high risk of cardiovascular diseases development. Early diagnose of this syndrome is especially important in population of people with mental disorders, because some disorders, such as schizophrenia, are associated with presence of some symptoms of metabolic syndrome, probably previous to pharmacotherapy. Some drugs used in treatment of mental disorders (among others antypsychotics: both typical and atypical) have unfavourable influence on weight gain, lipids profile and glucose metabolism disorders. In this article I present information about influence of antypsychotic treatment on the risk of metabolic syndrome development, can help to choose adquate, save pharmacotherapy for each patient, especially for patients with single symptoms of metabolic syndrome.
Get Citation

Keywords

schizophrenia; morbidity; mortality; metabolic syndrome; therapeutic restriction; choice of antipsychotic treatment

About this article
Title

Metabolic syndrome prevalence, morbidity and mortality in patients with schizophrenia. Therapeutic restrictions and choice of adequate antipsychotic

Journal

Psychiatria (Psychiatry)

Issue

Vol 3, No 4 (2006)

Article type

Review paper

Pages

148-153

Published online

2006-12-08

Bibliographic record

Psychiatria 2006;3(4):148-153.

Keywords

schizophrenia
morbidity
mortality
metabolic syndrome
therapeutic restriction
choice of antipsychotic treatment

Authors

Jolanta Rabe-Jabłońska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl